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Abstract  
Rationale: Arterial inflammation manifested as atherosclerosis is the leading cause of mortality 
worldwide. Genome-wide association studies have identified a prominent role of histone 
deacetylase 9 (HDAC9) in atherosclerosis and its clinical complications including stroke and 
myocardial infarction.  
Objective: To determine the mechanisms linking HDAC9 to these vascular pathologies and 
explore its therapeutic potential for atheroprotection.  
Methods and Results: We studied the effects of Hdac9 on features of plaque vulnerability using 
bone marrow reconstitution experiments and pharmacological targeting with a small molecule 
inhibitor in hyperlipidemic mice. We further employed two-photon and intravital microscopy to 
study endothelial activation and leukocyte-endothelial interactions. We show that hematopoietic 
Hdac9 deficiency reduces lesional macrophage content whilst increasing fibrous cap thickness 
thus conferring plaque stability. We demonstrate that HDAC9 binds to IKKα and β resulting in 
their deacetylation and subsequent activation, which drives inflammatory responses in both 
macrophages and endothelial cells. Pharmacological inhibition of HDAC9 with the class IIa 
HDAC inhibitor TMP195 attenuates lesion formation by reducing endothelial activation and 
leukocyte recruitment along with limiting pro-inflammatory responses in macrophages. 
Transcriptional profiling using RNA-Seq revealed that TMP195 downregulates key inflammatory 
pathways consistent with inhibitory effects on IKKβ. TMP195 mitigates the progression of 
established lesions and inhibits the infiltration of inflammatory cells. Moreover, TMP195 
diminishes features of plaque vulnerability and thereby enhances plaque stability in advanced 
lesions. Ex vivo treatment of monocytes from patients with established atherosclerosis reduced the 
production of inflammatory cytokines including IL-1β and IL-6. 
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Conclusion: Our findings identify HDAC9 as a regulator of atherosclerotic plaque stability and 
IKK activation thus providing a mechanistic explanation for the prominence of HDAC9 as a 
vascular risk locus in genome-wide association studies. Its therapeutic inhibition may provide a 
potent lever to alleviate vascular inflammation.  
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Nonstandard Abbreviations and Acronyms: 
GWAS Genome-wide association studies 
HDAC9 Histone deacetylase 9 
NF-κB  Nuclear factor-kappa-light-chain-enhancer of activated B-cells 
IKK  Inhibitory Kappa B Kinase 
GSK3β    Glycogen synthase kinase 3 beta 
RSK1   Ribosomal s6 kinase 
Apoe  Apolipoprotein e 
HUVECs  Human umbilical vein endothelial cells 
IκB-α  Inhibitor of kappa B  
BMDMs Bone marrow-derived macrophages 
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Introduction 
Arterial inflammation manifested as atherosclerosis is the main underlying pathology of 
cardiovascular disease including stroke and myocardial infarction 1. As a chronic inflammatory 
condition, atherosclerosis is orchestrated by numerous mediators of innate and adaptive immune 
responses 2, 3. Critical steps in atherogenesis include activation of the vascular endothelium and 
subsequent recruitment of immune cells. Inflammatory myeloid cells dominate both disease 
initiation and progression, while expansion of the necrotic core and fibrous cap thinning dictate 
plaque stability 4, 5. 
Histone deacetylases (HDACs) are signal-responsive regulators of gene expression with 
established roles in innate and adaptive immune pathways 6-8. Class IIa HDACs (HDAC4, 5, 7, 
and 9) shuttle between the cytoplasm and nucleus and control expression of key mediators of 
vascular inflammation 6. HDAC9 stands out as an important regulator of cell differentiation 9, 
proliferation 10, angiogenesis 11, glucose, and lipid metabolism 12, 13. We and others previously 
demonstrated a prominence of HDAC9 in human atherosclerosis by genome-wide association 
studies (GWAS) in stroke 14, 15, coronary artery disease and myocardial infarction 16, 
atherosclerotic aortic calcification 17, and peripheral artery disease 18. In spite of these striking 
associations, the mechanisms linking HDAC9 to vascular inflammation and the ensuing 
therapeutic potential remain poorly defined.  
Here, we set out to address this gap by combining experiments in genetic mouse models with 
pharmacological targeting. We show that HDAC9 regulates features of atherosclerotic plaque 
vulnerability and demonstrate binding of HDAC9 to the NF-κB activating kinases IKKα and IKKβ 
resulting in their deacetylation and subsequent activation. Moreover, pharmacological inhibition 
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of these HDAC9-dependent mechanisms stabilized atherosclerotic lesions in mice and limited the 
activation of monocytes obtained from patients with established atherosclerosis.   
 
Methods 
Mouse model of atherosclerosis  
Sample size for mouse experiments was determined by SigmaPlot 12.5 with 80% statistical power 
and an  error of 0.05 on the basis of previous experiments 19, 20. Mice were randomly assigned to 
groups and data collection and analysis were performed blinded. Data were excluded for mice with 
broken aortic root valves after sectioning of the heart or died during treatment. Hdac9–/–Apoe–/– 
mice were generated as previously described 21. Mice had ad libitum access to food and water and 
were housed in a specific pathogen-free animal facility under a 12 h light-dark cycle. All mice 
used were males and experiments were started when mice were 6-8 weeks old. For the treatment 
approach, Apoe–/– mice (B6.129P2-Apoe/J; Charles River Laboratories) were fed a Western-type 
diet containing 21% fat (TD88137, Ssniff) for 4 weeks to induce early atherosclerosis and in 
parallel received daily intraperitoneal (i.p.) injections of TMP195 (50 mg/kg, Axon Medchem) or 
DMSO (vehicle) control solvent22. To study the effects of TMP195 on established lesions, Apoe–
/– mice were fed a Western-type diet for 8 weeks and starting in the 5th week, received daily i.p. 
injections of TMP195 (50 mg/kg) or vehicle. Features of plaque vulnerability, determined as 
macrophage area x necrotic core area / smooth muscle cell area x collagen area 20, were examined 
in Apoe–/– mice that were fed Western-type diet for 11 weeks and starting in the 8th week, were 
treated with TMP195 (50 mg/kg) or vehicle. Atherosclerotic lesions were quantified on serial 
sections by histology and immunofluorescence. Cholesterol and triglyceride levels in plasma were 
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quantified using enzymatic assays (Cayman) according to the manufacturer’s protocol. All animal 
experiments were approved by the local ethics committee. 
 
Bone marrow transplantation  
Recipient Apoe–/– mice were exposed to a lethal dose of whole-body irradiation (2x 6.5Gy) a day 
before bone marrow transplantation and transplanted with bone marrow from Hdac9–/–Apoe–/– and 
control Hdac9+/+Apoe–/– donors. Irradiated mice were allowed to recuperate for 4 weeks on 
antibiotics before receiving Western-type diet for 11 weeks. 
 
Tissue Harvesting 
Mice were anesthetized using ketamine-xylazine or medetomidine-midazolam-fentanyl. Blood 
was obtained via cardiac puncture and the arterial tree was perfused through the left ventricle with 
0.9% sterile NaCl. Hearts were either fixed in 4% paraformaldehyde (PFA) or directly embedded 
in Tissue-Tek OCT for sectioning and quantification of atherosclerotic lesion sizes. For protein 
analysis via western blot, the whole aorta was dissected, flash-frozen and lysed in RIPA buffer 
containing complete EDTA-free phosphatase and protease inhibitors (Roche) using the Ika T8 
Ultra Turrax Tissue Homogenizer. Where indicated, carotid arteries were flash-frozen for RNA 
isolation and real time PCR analysis.  
 
Immunohistochemistry  
The extent of atherosclerosis was assessed in the aortic root by staining lipid depositions with Oil-
red O. Hearts were embedded in Tissue-Tek for cryosectioning. Atherosclerotic lesions were 
quantified in 5 µm transverse serial sections and averages calculated from 3-5 sections. Masson 
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trichrome staining was performed on both aortic root and paraffin-embedded aortic arch sections 
to analyze lesion size, collagen content, fibrous cap thickness, and necrotic core formation. 
Macrophages and smooth muscle cells (SMCs) were visualized by immunofluorescent staining for 
Cd68 (Sigma) or Mac2 (Cedarlane) followed by Alexa 488-conjugated affinity purified antibody 
(Jackson ImmunoResearch) and Sma-cy3 (Sigma), respectively. Nuclei were counterstained by 4', 
6-diamidino-2-phenylindol (DAPI). All images were recorded with a Leica DMLB fluorescence 
microscope and CCD camera, and quantification of lesion size and composition was performed 
using Image J analysis software.  
 
Intravital microscopy    
Cx3cr1gfp/wtApoe–/– mice were fed a Western-type diet for 4 weeks, and in parallel received 
TMP195 (50 mg/kg) or vehicle. Following cannulation of the right jugular vein with a catheter, 
antibodies against Ly6G (1A8, Biolegend) and CD11b (M1/70, eBioscience) were administered 
and allowed to circulate for 10 min to label myeloid cell subsets. Subsequently, the left carotid 
artery was surgically exposed and intravital microscopy was performed using an Olympus BX51 
microscope equipped with a Hamamatsu 9100-02 EMCCD camera and a 10x saline-immersion 
objective. Image acquisition and analysis was performed with the Olympus excellence software.  
 
Two-photon imaging of whole-mount tissue   
Cx3cr1gfp/wtApoe–/– mice were fed a Western-type diet for 4 weeks, and in parallel received 
TMP195 (50 mg/kg) or vehicle. Fresh carotid arteries were explanted and mounted on glass 
micropipettes at a pressure of 80 mmHg. CD31 and VCAM-1 expression were quantified using 
CD31 (#48031182, eBioscience) and VCAM-1 (#105724, Biolegend) antibodies. The samples 
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were imaged using a Leica SP5IIMP two-photon laser scanning microscope with a pre-chirped 
and pulsed Ti:Sapphire Laser (Spetra Physics MaiTai Deepsee) tuned at 790nm and a 20×NA1.00 
(Leica) water dipping objective. Image acquisition and processing was performed using LasX 
software (Leica).  
 
Patient population and blood sampling 
Patients with acute ischemic stroke were recruited in 2017 through the stroke service, Klinikum 
der Universität München (KUM), a tertiary level hospital at Ludwig-Maximilians-Universität 
(LMU), Munich, Germany. Patients were selected based on the presence of carotid atherosclerosis 
(carotid artery plaques or carotid artery stenosis) documented by carotid ultrasound. Whole blood 
was drawn into EDTA-plasma containers (Sarstedt) using a tourniquet and 21-gauge needles. The 
study was approved by the local ethics committee and was conducted in accordance with the 
Declaration of Helsinki as well as institutional guidelines. Written and informed consent was 
obtained from all subjects. 
 
Isolation of human monocytes  
Human Peripheral Blood Mononuclear Cells (PBMCs) were isolated from whole blood by Ficoll-
Paque (GE Healthcare) density gradient centrifugation and were enriched for monocytes with the 
Monocyte Isolation Kit II (Miltenyi Biotec) according to manufacturer’s recommendation. A 
cocktail of biotin-conjugated antibodies was used to label non-monocytes. Depletion of these 
labeled cells resulted in enriched monocytes.   
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Primary cell culture, transfection and gene silencing 
Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from PromoCell, plated on 
cell culture dishes coated with collagen (Biochrom AG), cultured in endothelial cell growth 
medium (PromoCell) according to manufacturer’s recommendations and used between passages 5 
and 8. Transfection of HUVECs with predesigned ON-TARGETplus SMARTpool human HDAC9 
siRNA or Non-targeting control (Dharmacon) was conducted by electroporation using the HUVEC 
Nucleofector Kit (Lonza) following the manufacturer’s instructions. Where indicated, plasmid 
DNA was co-transfected. Cells recuperated for 48 h or 72 h before entering the experiment. 
HUVEC were stimulated with 20 ng/ml human TNF-α (PeproTech) at different time intervals.  
 
Generation of bone marrow-derived macrophages  
Bone marrow-derived macrophages (BMDMs) were generated as established by flushing the bone 
marrow from femurs and tibiae with ice-cold PBS, resuspending in PBS by repeated pipetting and 
filtering through a 40 µm cell strainer (BD Biosciences). After centrifugation of the cell suspension 
at 500 g for 10 min, the pellet was resuspended in culture medium (RPMI 1640 containing 10% 
FCS, 15% L929-cell-conditioned medium (LCM) and 100 µl/ml gentamycin) and plated on 15 cm 
untreated culture plates (Greiner). 15 % fresh L929-conditioned medium (LCM) was added again 
on day 1 and 2 of culturing. For stimulation experiments, differentiated macrophages were 
harvested by gentle scraping, transferred onto untreated 6-well or 12-well plates (Greiner) on Day 
7 of culturing and left in LCM-free medium for 24 hours, allowing cells to adhere. Cells were then 
stimulated in FCS-free medium with either 50 ng/ml mouse recombinant Tnf-α at different time 
intervals or left untreated. 
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Flow cytometry 
Aorta and EDTA-buffered blood samples were harvested and a single-cell suspension was 
prepared and filtered over a 70 µm cell strainer (Greiner). Cells were treated with erythrocyte lysis 
buffer (0.155 M NH4Cl, 10 mM NaHCO3). All cell suspensions were carefully washed and stained 
with FACS staining buffer and combinations of antibodies against Cd45, Cd11b, Cd3, B220, Ly6G 
(eBioscience), and Ly6C (Miltenyi Biotec). Flow cytometry analysis was performed using 
FACSVerse and FACSuite software (BD Biosciences) after appropriate fluorescence 
compensation, and leukocyte subsets were gated using FlowJo software (Treestar). B cells were 
identified as Cd45+B220+; T cells as Cd45+Cd3+; neutrophils as Cd45+CD11b+Ly6G+; monocytes 
as Cd45+Cd11b+Ly6C+.  
 
RNAseq analysis 
BMDMs were isolated from Apoe–/– mice as established and briefly described above. Cells were 
pretreated with either TMP195 (5 µM) or TPCA-1 (500 nM) for 1 h prior to stimulation with TNF-
α (50 ng/ml) for 24 h. Total RNA was isolated using Trizol (Invitrogen) and RNA library prepared 
according to Illumina RNA Seq library kit instructions. Quality control and quantification of RNA 
and library were performed using an Agilent 2100 Bioanalyzer and a Kapa Library Quantification 
Kit (Kapa Biosystems), according to the manufacturer’s protocol. cDNA fragments was amplified 
with Illumina’s cBot. Libraries were loaded at a concentration of 10 pM onto flow cells and 
sequenced on an Illumina HiSeq 1500 platform.  
For sequence analysis of RNA reads, 50 nt single-end reads were mapped to the GRCm38 
reference genome using STAR software version 2.6.1d. TPM expression values based on 
ENSEMBL annotation version GRCm38.95 were calculated with RSEM (1.3.0). We used the 
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DESeq2 Bioconductor R package to identify differentially expressed genes at a false discovery 
rate (FDR) of 10%. Gene ontology enrichment was determined using 'topGO' (2.36.0), Gene set 
enrichment analysis (GSEA) was performed using the 'fgsea' package (1.10.0).  
 
Quantitative real-time PCR 
RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse-transcribed using oligodT 
primers (Metabion). RT-PCR analysis was performed using Brilliant II SYBR Green QPCR 
Master Mix (Agilent Technologies) in a Light cycler 480 (Roche Diagnostics). GAPDH, HPRT1 
or 18S were used as housekeeping genes, as appropriate. Measurements were performed in 
triplicates. The 2−ΔΔCt method was used to calculate relative expression changes. 
 
ELISA 
Cytokine levels in mouse plasma were measured using a commercially available kit for Ccl2 
(Invitrogen). For cytokine secretion, BMDMs were stimulated with 50 ng/ml mouse Tnf-α 
(Peprotech) for the indicated times. Levels of Cxcl1, Il-1β, Il-6, Tnf-α and Ccl2 were assayed in 
the supernatant using commercially available ELISA kits (R&D systems). Likewise, the secretion 
of human TNF-α, CCL2, IL-1β and IL-6 were quantified using commercially available ELISA kits 
(Invitrogen and R&D systems).  
 
Cell lysis, co-immunoprecipitation and Western blot analysis  
For total cell lysates, cells were washed with cold PBS and lysed either directly with 1x NuPAGE-
LDS-sample buffer (Invitrogen) containing 1 mmol/l DTT (Sigma Aldrich) or with 1x cell lysis 
buffer (#9803, Cell signaling). Protease and phosphatase inhibitors (Roche) were added to all 
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buffers. For immunoprecipitation experiments, HEK293 cells were transiently co-transfected with 
Flag-HDAC9 and the specific component of the NF-κB pathway under assessment: HA-IKKβ (In 
vivoGen); HA-IKKα (In vivoGen); HA-IKKγ; HA-IκBα; HA-GSK3β or HA-RSK1. pcDNA3 HA 
human NEMO was a gift from Kunliang Guan (Addgene plasmid # 13512). pCMV4-3 HA/IκB-α 
was a gift from Warner Greene (Addgene plasmid # 21985). HA GSK3 beta wt pcDNA3 was a 
gift from Jim Woodgett (Addgene plasmid # 14753). pKH3-human RSK1 was a gift from John 
Blenis (Addgene plasmid # 13841). Cells were treated with 1µM MG132 for 1 h to prevent 
proteasomal degradation prior to lysis. Following incubation of 250 µg of protein with 10 µg of 
primary antibody (anti-Flag or anti-HA) overnight at 4°C, the ensuing protein complexes were 
incubated with protein A or G beads for 2 h. Antibody-antigen complexes were eluted from the 
beads after washing with 1x cell lysis buffer containing 150 mM NaCl and a final stringent wash 
with 250 mM NaCl. For subcellular fractionation, nuclear extracts were isolated using a subcellular 
fractionation kit following the manufacturer’s protocol (Active Motif). Total cell lysates, nuclear 
extracts or coimmunoprecipitated proteins were separated by SDS-PAGE, transferred to a PVDF 
membrane (Bio-Rad), and detected with the appropriate antibodies. Primary antibodies were 
incubated overnight at 4⁰C. HRP-conjugated anti-mouse or anti-rabbit antibodies were used as 
secondary antibodies and blots were developed with Immobilon Western HRP Substrate (Merck 
Millipore). Protein bands were visualized with a Fusion Fx7 and quantified using Image J 1.47v 
software (Wayne Rasband). 
 
Kinase activity assay  
HEK293 cells were transfected with either Flag-HDAC9 and HA-IKKβ or Flag-alone and HA-
IKKβ and subsequently lysed in ice-cold 1x cell lysis buffer (#9803, Cell Signaling) supplemented 
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with protease and phosphatase inhibitors. Immunoprecipitation of IKKβ and HDAC9 were 
performed as described above with anti-HA and anti-Flag antibody, respectively. The 
immunoprecipitated complexes were washed three times with ice-cold 1x cell lysis buffer and 
three times with ice-cold 1x kinase buffer (#9802, Cell Signaling). Thereafter, the complexes were 
incubated with recombinant p65 (400 ng) as substrate at 34°C for 45 min in the presence of 100 
µM ATP. Reactions were stopped by the addition of 4x Laemmli sample buffer followed by 
incubation at 95°C for 20 min. Proteins were separated on 7% SDS-PAGE and immunoblotted for 
p65 phosphorylation using anti-NF-κB p65 (phospho S536) antibody.   
 
Confocal microscopy 
HUVECs were transfected with HDAC9 siRNA or scrambled control RNA and stimulated at 
different time intervals with TNF-α. Cells were washed with 1x PBS, fixed with 4% PFA-PBS 
solution for 10 minutes and permeabilized using 0.1% Triton X. Cells were then blocked for 1 h 
with 0.2% FCS, 0.2% BSA and 0.002% fish skin gelatin in 1x PBS. In the same solution, the 
primary antibody for p65 was incubated overnight at 4°C. DAPI and Alexa Fluor 488-labeled 
secondary antibodies were incubated for 1 h at room temperature. Cells were washed and sealed 
with a coverslip coated in fluoromount mounting medium (Sigma). Imaging was performed with 
the confocal microscope (LSM 880, Zeiss) using the 40x oil objective and analyzed with the ZEN 
software (Zeiss).  
 
Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 6 (GraphPad Software Inc.). Data are 
represented as means ± s.e.m. After testing for normality, data were analyzed by two-tailed 
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unpaired Student’s t test or Mann–Whitney test or Fisher’s exact test, one-way or two-way 
ANOVA with Bonferroni or Holm-Sidak multiple comparison test or Fisher’s LSD test or Kruskal-
Wallis with Dunn’s multiple comparison test, as appropriate. P values <0.05 were considered to 
be statistically significant. 
 
Results 
Hdac9 promotes pro-inflammatory responses and enhances features of atherosclerotic 
plaque vulnerability 
To study the role of Hdac9 in vascular inflammation, we used mouse models of atherosclerosis. 
Lethally irradiated Apoe–/– mice were reconstituted with bone marrow from either Hdac9+/+Apoe–
/– (Hdac9+/+ BM) or Hdac9–/–Apoe–/– mice (Hdac9–/– BM) and were fed a Western-type diet for 11 
weeks followed by analysis of aortic root lesions (Fig. 1a). Reconstitution with Hdac9-deficient 
bone marrow was atheroprotective with smaller lesion sizes and a lower proportion of advanced 
lesions compared to control bone marrow (Fig. 1b-d), while lipid levels, body weight, and 
circulating leukocyte counts did not differ between groups (table S1). To determine features of 
plaque vulnerability we focused on advanced lesions. Hdac9 deficiency in hematopoietic cells 
lowered lesional macrophage content and necrotic core size and increased fibrous cap thickness 
thus reducing overall plaque vulnerability (Fig. 1e-j and fig. S1a-c). Moreover, Hdac9-deficient 
bone marrow-derived macrophages (BMDMs) showed reduced TNF-induced upregulation of 
pro-inflammatory cytokines and chemokines on mRNA and protein level (Fig. 1k-m). 
Collectively, these findings indicate that Hdac9 promotes pro-inflammatory responses in the bone 
marrow-derived compartment of the vasculature and enhances features of atherosclerotic plaque 
vulnerability.  
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HDAC9 binds to IKKα and IKKβ resulting in their deacetylation and activation 
The mechanisms linking HDAC9 to vascular inflammation and plaque instability are unknown. In 
light of the central role of NF-κB in atherosclerosis and the resemblance of HDAC9-related 
inflammatory gene expression with NF-κB-driven transcriptional responses 23, we hypothesized 
that NF-κB might be a downstream effector of HDAC9 (Fig. 2a). Co-immunoprecipitation 
experiments revealed a complex involving HDAC9, IKKα, and IKKβ but not IKKγ, IκBα, and the 
non-canonical kinases GSK3β and RSK1 (Fig. 2b and fig. S2a). Of note, we detected IKKα and 
IKKβ upon HDAC9 pulldown and vice versa (fig. S2b, c). To investigate the functional 
consequence of these interactions, we determined the acetylation status of IKKα and IKKβ and 
found reduced acetylation of both kinases in the presence of HDAC9 (Fig. 2c, d). This was 
accompanied by enhanced activity of IKKβ as evidenced by increased phosphorylation of p65 in 
the presence of HDAC9 in an in vitro kinase activity assay (Fig. 2e and fig. S2d) in accord with 
the established inhibitory effect of acetylation on IKK activation 24. IKKβ phosphorylates p65 at 
serine residues 536 and 468, while IKKα phosphorylates p65 at 536 25. We therefore examined the 
effect of HDAC9 on p65 phosphorylation at these residues as an endogenous readout for the 
activation of IKK. Indeed, Hdac9-deficient BMDMs showed reduced Tnf-α-induced 
phosphorylation at both serine 536 and 468 (Fig. 2f, g). Given the pivotal role of NF-κB in driving 
pro-inflammatory responses in the vascular endothelium, we extended our findings to endothelial 
cells. siRNA-mediated knockdown of HDAC9 in human umbilical vein endothelial cells 
(HUVECs) likewise reduced p65 phosphorylation at serine 536 and 468 without affecting 
phosphorylation at serine 276 (Fig. 2h, i) which is mediated by MSK1, PIM1, and PKAc 25. In 
contrast, we found no effect of HDAC9 on ERK1/2 and p38MAPK signaling (fig. S3a-d), further 
corroborating the specificity of the downstream signaling events induced by HDAC9/IKK 
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interactions. The reduced phosphorylation of p65 upon HDAC9 knockdown was accompanied by 
reduced nuclear localization of p65 (Fig. 2j-l and fig. S3e, f) and a subsequent decrease in de novo 
synthesis of IκB-α (fig. S4a-d). Consequently, the expression of prototypical NF-κB -driven pro-
inflammatory target genes was reduced both in HDAC9-depleted HUVECs and in Hdac9-deficient 
mice (Fig. 2m and fig. S5a-l). Collectively, these findings define the IKK/NF-κB pathway as a 
major downstream effector linking HDAC9 to vascular inflammation. 
 
Pharmacological inhibition with TMP195 attenuates the initiation of atherosclerosis 
To assess the therapeutic implication of our observations, we utilized TMP195, a selective class 
IIa HDAC inhibitor with high affinity for HDAC9 22, 26, in a mouse model of atherogenesis 
constituting important features of endothelial activation and myeloid cell recruitment.  Apoe–/– 
mice were fed Western-type diet for 4 weeks and in parallel received TMP195 or vehicle (Fig. 
3a). TMP195 attenuated early lesion formation (Fig. 3b, c) and reduced endothelial activation as 
demonstrated by mitigated Vcam-1 expression (Fig. 3d, e and fig. S6a). Accordingly, the invasion 
of monocytes and neutrophils into atherosclerotic lesions was reduced in TMP195-treated mice 
(Fig. 3f, g and fig. S6b, c) likely attributable to impaired leukocyte-endothelial interactions as 
demonstrated by a reduction of myeloid cell rolling and adhesion to carotid arteries (Fig. 3h-k and 
fig. S6d-f). Hence, treatment with TMP195 confers atheroprotection by limiting leukocyte 
recruitment into atherosclerotic lesions.  
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TMP195 limits pro-inflammatory responses consistent with reduced activation of IKKβ 
NF-κB takes center stage in regulating adhesion molecules and chemokines involved in leukocyte-
endothelial interactions at the vascular wall 23. Given our findings on the activating effect of 
HDAC9 on NF-κB (Fig. 2), we examined the consequence of TMP195 treatment on NF-κB 
activity. TMP195 enhanced the acetylation (Fig. 4a, b) and reduced the activity of IKKβ as 
demonstrated by reduced phosphorylation of p65 in HEK293 cells, and in BMDMs (Fig. 4c-e). 
Accordingly, TMP195 inhibited NF-κB-driven cytokine and chemokine expression, which have 
established roles in vascular inflammation (Fig. 4f), thus essentially paralleling our data upon gene 
silencing of Hdac9 (Fig. 2m). The prominent inhibitory effect of TMP195 on pro-inflammatory 
responses in macrophages prompted us to examine the transcriptome of TMP195-treated BMDMs 
stimulated with Tnf-α. Gene expression profiling showed that TMP195 downregulated key 
inflammatory pathways including ‘cell surface interactions at the vascular wall’ and ‘cytokine 
signaling in immune system’ (Fig. 4g). Moreover, out of 272 differentially regulated genes in 
TMP195-treated BMDMs, 85 overlapped with those induced by treatment with the IKKβ inhibitor 
TPCA-1 27 with consistent directionality in 86% (73/85) of overlapping genes (Fig. 4h and fig. 
S7a). Further analysis revealed that co-treatment with both inhibitors had no additive effect on 
cytokine and chemokine expression (Fig. 4i), consistent with the hypothesis that the anti-
inflammatory effects of TMP195 are mediated, at least in part, through inhibitory effects on IKKβ.  
 
Therapeutic inhibition with TMP195 reduces atheroprogression and confers plaque stability 
Preventive treatment in patients at risk for cardiovascular disease is typically initiated at a stage 
when lesions already exist. Hence, we explored the therapeutic effects of TMP195 on established 
atherosclerosis. Apoe–/– mice receiving Western-type diet for 8 weeks were treated with TMP195 
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or vehicle starting from the 5th week of diet, when lesions had developed (Fig. 5a). TMP195 
attenuated the progression of established atherosclerosis as revealed by a reduction of lesion sizes 
in comparison with vehicle-treated mice (Fig. 5b, c and fig. S7b-d). TMP195 further reduced the 
invasion of classical monocytes and neutrophils into atherosclerotic lesions (Fig. 5d and fig. S7e). 
Importantly, TMP195 exhibited pronounced atheroprotective effects even at later stages when 
initiating treatment from the 8th week of diet (Fig. 5e). TMP195 attenuated advanced lesion size, 
reduced necrotic core formation, and increased fibrous cap thickness along with a trend for 
increased smooth muscle cell content resulting in a more stable plaque phenotype (Fig. 5f - k and 
fig. S8 a-c). This was consistent with reduced NF-κB target gene expression in advanced lesions 
in TMP195-treated mice (Fig. 5l). Hence, aside from exerting beneficial effects on early 
atherogenesis, TMP195 attenuates progression of existing atherosclerotic lesions and confers 
plaque stability.  
Given the effects of TMP195 on vascular inflammation and atheroprogression as well as plaque 
stability in mice, we further analyzed the activation of monocytes from patients with athero-
sclerosis (Fig. 5m and table S2). Specifically, we determined the effect of ex vivo treatment with 
TMP195 or vehicle on phosphorylation of p65 and cytokine production after stimulation with 
TNF-α. TMP195 reduced phosphorylation of p65 at serine 536 resulting in a significantly reduced 
production of cytokines and chemokines including IL-1β and IL-6 (Fig. 5n-p). Collectively, these 
results demonstrate that therapeutic inhibition with TMP195 induces a stable plaque phenotype in 
mice and limits the activation of monocytes from patients with atherosclerosis.  
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Discussion 
Our findings provide a mechanistic explanation for the prominence of HDAC9 as a vascular risk 
locus in genome-wide association studies (GWAS) and suggest that therapeutic targeting of 
HDAC9 may provide a potent strategy for preventing vascular inflammation. This conclusion is 
supported by i) the increase in atherosclerotic plaque stability conferred by genetic depletion of 
Hdac9 as well as pharmacological inhibition with class IIa HDACi; ii) the activating effect of 
HDAC9 on IKK in macrophages and vascular endothelial cells; and iii) the reduced activation of 
monocytes from patients with atherosclerosis upon ex vivo inhibition of this HDAC9-dependent 
pathway by treatment with small molecule inhibitor TMP195.  
Inflammatory and immune responses are governed by mechanisms of transcriptional 
regulation 28-32 and modulating these mechanisms may limit vascular inflammation. HDAC 
inhibitors are powerful transcriptional regulators that are in clinical use for some conditions 
including T cell lymphoma 7, 33. Yet, broad-spectrum HDAC inhibitors (HDACi) have contra-
indications limiting their application in cardiovascular disease 33, 34. In fact, treatment with 
trichostatin A has been shown to exacerbate atherosclerotic lesion size 34 despite an anti-
atherogenic function in M 35. This might relate to distinct and even opposing roles of individual 
HDACs in atherosclerosis 12, 21, 36, 37 or differential actions of broad-spectrum HDACi on individual 
HDACs. Our findings reveal vascular protective effects of class IIa HDAC inhibition with 
TMP195 thus overcoming a central limitation to the use of broad-spectrum HDACi 34. Whether 
further restricting the inhibitory activity to individual HDACs 33 or specifically targeting M 36 
and ECs 37, 38, for instance by nano-delivery strategies 39, would confer additional benefit remains 
to be shown.   
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The previously unrecognized activating effect of HDAC9 on NF-κB signaling as unraveled 
here offers a strategy for fine-tuning NF-κB responses to reduce vascular inflammation 19, 40, 41. 
This involves HDAC9-mediated deacetylation and subsequent activation of IKK potentially as 
part of a larger molecular complex. NF-κB signaling is modulated by phosphorylation of its 
subunits. Phosphorylation of p65 either transactivates or inhibits NF-κB activity depending on the 
kinases and specific residues involved. IKK phosphorylates p65 at serine 536 and 468, enhances 
transactivation, and directs transcription in a target gene-specific manner 42, 43. Of note, our finding 
that HDAC9 is required for sustained p65 phosphorylation at serines 536 and 468 fits with the 
pattern of reduced inflammatory cytokines, chemokines, and adhesion molecules demonstrated 
here in various experimental paradigms of HDAC9 inactivation or depletion.    
Drug targets with support from human genetics have a higher probability of reaching phase 
III clinical trials and regulatory approval 44, 45. GWAS in a broad range of vascular conditions 14-18 
highlight an exceptional role of the HDAC9 region in major complications of human 
atherosclerosis. As such, our current findings in mice and in isolated cells including human 
monocytes provide triangulation of evidence 46 for HDAC9 as a causal factor in atherosclerosis 
and a promising target for interventional studies in humans. The inhibitory effect of TMP195 on 
the secretion of inflammatory cytokines including IL-1β and IL-6 in monocytes from patients with 
atherosclerosis would further agree with the concept of targeting the residual inflammatory risk in 
high-risk populations 47, 48.  
Treatment with TMP195 limited features of plaque vulnerability consistent with results 
obtained in Hdac9-deficient mice. As a potential limitation, our animal models do not fully reflect 
the phenotype of human atherosclerotic plaques, which includes plaque destabilization and rupture 
with occlusive thrombosis. Also, developing class IIa HDAC inhibitors with even higher 
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specificity for HDAC9 may be needed to exploit the full potential of HDAC9 inhibition for the 
prevention of atherosclerosis. 
In summary, we demonstrate that HDAC9 promotes pro-inflammatory responses in the 
vasculature to augment features of atherosclerotic plaque vulnerability. HDAC9 binds to IKKα 
and β resulting in their deacetylation and subsequent activation, which drives vascular 
inflammation. Treatment with TMP195, a selective class IIa HDAC inhibitor, inhibits key 
inflammatory pathways, attenuates atherogenesis, atheroprogression, and late-stage 
atherosclerosis, and confers plaque stability, thus defining a novel therapeutic strategy to reduce 
the burden of vascular inflammation. 
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Figure Legends 
Fig. 1. Hdac9 promotes pro-inflammatory responses and enhances atherosclerotic plaque 
vulnerability. a – j, Experimental outline. Lethally irradiated Apoe–/– mice were reconstituted with 
bone marrow from either Hdac9–/–Apoe–/– (Hdac9–/– BM) or Hdac9+/+Apoe–/– (Hdac9+/+ BM) mice 
and were fed a Western-type diet for 11 weeks to induce advanced atherosclerosis (a). b, 
Representative image of Oil-Red-O stained aortic root lesion. Scale bars, 200 µm. c, Quantification 
of lesion sizes. d, Lesion classification on Masson Trichrome stained sections. Two-sided Mann–
Whitney test (c) and two-sided Fisher’s exact test (d). Quantification of necrotic core area (e), 
representative immunostainings (f) showing lesional CD68+ macrophage area in red and SMA+ 
smooth muscle cell area in green. Scale bars, 100 µm. g) Quantification of macrophage area.  h, 
Overall vulnerability. i, Representative Masson Trichrome stained lesions with fibrous cap (FC) 
indicated with arrow heads.  Scale bars, 50 µm. j, Quantification of FC thickness. Two-sided 
unpaired t-test. k – m, BMDMs isolated from Hdac9–/–Apoe–/– and Hdac9+/+Apoe–/– mice were 
either stimulated with Tnf-α (50 ng/ml) or left untreated (k). Quantification of gene expression 
(after 6 h of Tnf-α stimulation; l) and secretion (after 24 h of Tnf-α stimulation; m) of key pro-
inflammatory chemokines and cytokines. Two-way Anova with Bonferroni correction. Data are 
mean ± s.e.m. 
 
Fig. 2. HDAC9 binds to IKKα and IKKβ resulting in their deacetylation and activation. a, 
Schematic representation of the canonical NF-κB pathway. b – e, HEK293 cells were transiently 
co-transfected with Flag-HDAC9 and individual components of the IKK complex (HA-IKKα; 
HA-IKKβ; or HA-IKKγ).  b, Representative immunoblots depicting the interaction between 
HDAC9 and IKK. n=2-4 independent experiments. c, Representative immunoblots of acetylated 
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IKKα and IKKβ and their non-acetylated forms. d, Quantification of acetylated IKKα and IKKβ 
normalized to non-acetylated forms. Two-sided Mann–Whitney test. e, Representative 
immunoblots of kinase activity assay. n=2 independent experiments. f, Representative 
immunoblots showing p65 phosphorylation at serine residues 536 and 468, and corresponding 
non-phosphorylated forms in Tnf-α-stimulated Hdac9-deficient versus control BMDMs. g, 
Quantification of p-p65 (S536, 45 min; and S468, 5 min of Tnf-α stimulation) normalized to total 
p65. Two-sided unpaired t-test. h – m, HUVECs were transiently transfected with HDAC9 siRNA 
or scrambled control (SCR) RNA for 72 h and subsequently stimulated with TNF-α (20 ng/mL) 
for indicated periods or left untreated. h, Representative immunoblots showing p65 
phosphorylation at serine residues 536, 468, and 276 and corresponding non-phosphorylated 
forms. i, Quantification of p-p65 (S536, 120 min; and S468, 5 min of Tnf-α stimulation) 
normalized to total p65. Two-sided unpaired t-test (S536) and two-sided Mann–Whitney test 
(S468).  j, Determination of nuclear localization of p65 by confocal microscopy. Shown are 
representative immunostainings of three independent experiments. Scale bar, 10 µm. k, 
Representative immunoblots of nuclear p65 and lamin B1. l, Quantification of nuclear p65 
normalized to lamin B1. Two-way Anova with Bonferroni correction.  m, Gene expression 
analysis by RT-PCR after 8 h of TNF- α stimulation. Two-way Anova with Bonferroni correction. 
Data are mean ± s.e.m.  
 
Fig. 3. TMP195 attenuates the initiation of atherosclerosis. a – g, Experimental outline. Apoe–
/– mice were fed Western-type diet for 4 weeks and in parallel received TMP195 (50 mg/Kg) or 
vehicle (a). b, Representative Oil-Red-O stained aortic root lesion. Scale bars, 200 µm. c, 
Quantification of lesion sizes. Two-sided unpaired t-test. d, Representative immunostaining of 
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Vcam-1 in carotid arteries visualized by two-photon microscopy. Scale bars, 50 µm. e, 
Quantification of Vcam-1 expression. Two-sided Mann–Whitney test. f, g, Analysis of leukocyte 
accumulation in atherosclerotic aortas by flow cytometry. Quantification of aortic Ly6Chigh 
monocytes f) and aortic Ly6G+ cells g). Two-sided unpaired t-test. h – k, Cx3cr1gfp/wtApoe–/– mice 
were fed a Western-type diet for 4 weeks, and in parallel received TMP195 (50 mg/kg) or vehicle. 
Examination of leukocyte-endothelial interaction by intravital microscopy. Representative image 
of CD11b+ adhesion h). Scale bars, 100 µm. Quantification of adherent CD11b+ cells i), adherent 
Ly6C+ cells j), and adherent Ly6G+ cells k).  Two-sided unpaired t-test. Data are mean ± s.e.m. 
 
Fig. 4. TMP195 limits pro-inflammatory responses consistent with reduced activation of 
IKKβ. a, b, Following transfection of IKKβ, HEK293 cells were treated with vehicle or TMP195. 
a, Representative immunoblots of acetylated and total IKKβ. b, Quantification of acetylated IKKβ 
normalized to total IKKβ. Two-sided Mann–Whitney test. c, Determination of kinase activity. n = 
2 independent experiments. d, e, BMDMs generated from Apoe–/– mice were pretreated with 
varying concentrations of TMP195 or vehicle for 1 h and either stimulated with Tnf-α (50 ng/mL) 
or left untreated. d, Representative immunoblots of phosphorylated p65 at serine 536 and total p65 
after 5 min of Tnf-α stimulation. e, Quantification of phosphorylated p65 normalized to total p65. 
n=8 independent experiments. One-way Anova with Holm-Sidak’s correction. f, Analysis of gene 
expression by RT-PCR after 24 h of Tnf-α stimulation.  One-way Anova with Holm-Sidak’s 
correction. g, h, BMDMs generated from Apoe-/- mice were treated with TMP195 (5 µM) or TPCA-
1 (500 nM) for 1 h prior to stimulation with Tnf-α (50 ng/mL) for 24 h followed by RNA 
sequencing. g, Downregulated reactome pathways upon TMP195 treatment. h, Venn diagram 
depicting overlap between differentially regulated genes upon inhibition with TMP195 or TPCA-
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1. TMP195 (n=5 mice) and TPCA-1 (n=5 mice). Results are log2 fold change >1 or <-1 with Padj 
≤ 0.1. i, BMDMs generated from Apoe-/- mice were treated with TMP195 (5 µM), TPCA-1 (500 
nM), or co-treated with both inhibitors for 1 h prior to stimulation with Tnf-α for 24 h. Gene 
expression of key pro-inflammatory chemokines and cytokines was quantified by RT-PCR. One-
way Anova with Fisher’s LSD test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001. Data are 
mean ± s.e.m. 
 
Fig. 5. Therapeutic inhibition with TMP195 reduces atheroprogression and confers plaque 
stability. a – d, Experimental outline. Apoe–/– mice receiving Western-type diet for 8 weeks were 
treated with TMP195 (50 mg/kg) or vehicle starting from the 5th week of diet, when lesions have 
already developed (a). b, Representative Oil-Red-O stained aortic root lesions. Scale bars, 200 
µm. c, Quantification of lesion sizes. Two-sided Mann–Whitney test. d, Analysis of classical 
Ly6Chi monocytes in atherosclerotic aortas. Two-sided unpaired t-test. e – k, Experimental outline. 
Apoe–/– mice receiving Western-type diet for 11 weeks were treated with TMP195 (50 mg/kg) or 
vehicle starting from the 8th week of diet (e). f, Representative Sirius red stained lesions in the 
brachiocephalic artery. Scale bars, 100 µm. Quantification of lesion sizes g), necrotic core area h), 
fibrous cap (FC) thickness i), smooth muscle cell area j), and vulnerable plaque index k). Two-
sided unpaired t-test or Mann–Whitney test. l, Quantification of gene expression in atherosclerotic 
aortas. Two-sided Mann-Whitney test. m – p, Monocytes were freshly isolated from patients with 
established atherosclerosis and treated ex vivo with TMP195 or vehicle for 1 h prior to stimulation 
with TNF-α (50 ng/mL; m). n, Representative immunoblots of phosphorylated p65 at serine 536 
and total p65 after 5 min of TNF-α stimulation. o, Quantification of phosphorylated p65 
normalized to total p65 (n) and cytokine production after 24 h of TNF-α stimulation (p). One-way 
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Anova with Holm-Sidak’s correction o). Two-sided unpaired t-test or Mann–Whitney test p). Data 
are mean ± s.e.m. 
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